Purchase disclosed
Michael R. Hayden
Director
Common Shares
- Reported value
- $570.44K
- Reported price
- $10.64 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
AbCellera Biologics Inc.
Last 30 daysNo qualifying insider buying. No qualifying insider sales.
Director
Common Shares
Director
Common Shares
Chief Financial Officer
Common Shares
Director
Common Shares
Director
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common SharesPurchase | 53,613$10.64 / share | $570.44K | Aug 24Filed Aug 24 · 0d later | SEC filing |
| Director | Common SharesPurchase | 10,000$11.03 / share | $110.3K | Aug 18Filed Aug 18 · 0d later | SEC filing |
| Chief Financial Officer | Common SharesPurchase | 37,200$10.32 / share | $383.9K | Aug 14Filed Aug 14 · 0d later | SEC filing |
| Director | Common SharesPurchase | 46,387$10.37 / share | $481.03K | Aug 12Filed Aug 14 · 2d later | SEC filing |
| Director | Common SharesPurchase | 20,000$4.77 / share | $95.4K | May 14Filed May 18 · 4d later | SEC filing |
$1,183,110 of common-equity purchase value after transaction-age decay across 180 days.
3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.